Calibrating disease progression models using population data: a critical precursor to policy development in cancer control (Q30496883)

16 October 2017

Calibrating disease progression models using population data: a critical precursor to policy development in cancer control (English)

1 reference

16 October 2017

1 reference

Roman Gulati

1

1 reference

16 October 2017

Lurdes Inoue

2

1 reference

16 October 2017

Jeffrey Katcher

3

1 reference

16 October 2017

William Hazelton

4

1 reference

16 October 2017

Ruth Etzioni

5

1 reference

16 October 2017

7 June 2010

1 reference

16 October 2017

1 reference

16 October 2017

11

1 reference

16 October 2017

4

1 reference

16 October 2017

707-719

1 reference

maintained by WikiProject

16 October 2017

WikiProject Mathematics

0 references

cites work

Modeling Disease Progression with Longitudinal Markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Lead time associated with screening for prostate cancer.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

The influence of finasteride on the development of prostate cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Multistage carcinogenesis and the incidence of colorectal cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Prostate-specific antigen as predictor of prostate cancer in black men and white men.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration.

14 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FBIOSTATISTICS%2FKXQ036

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBIOSTATISTICS%2FKXQ036

Asymptomatic incidence and duration of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBIOSTATISTICS%2FKXQ036

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBIOSTATISTICS%2FKXQ036

The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBIOSTATISTICS%2FKXQ036

Electrochemical stimulation of the median eminence evokes FSH but not LH release after LHRH antagonist treatment in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBIOSTATISTICS%2FKXQ036

Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBIOSTATISTICS%2FKXQ036

A Simplex Method for Function Minimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBIOSTATISTICS%2FKXQ036

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBIOSTATISTICS%2FKXQ036

Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2950791

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

26 November 2018

1 reference

12 December 2020

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

12 December 2020

Age-specific reference ranges for serum prostate-specific antigen

1 reference

12 December 2020

A population model of prostate cancer incidence

1 reference

12 December 2020

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach

1 reference

12 December 2020

10.1093/BIOSTATISTICS/KXQ036

Identifiers

DOI

1 reference

16 October 2017

1 reference

16 October 2017

PubMed publication ID

20530126

1 reference